GSK pays up to $230M on J&J deal for asthma antibody

Lungs

GlaxoSmithKline ($GSK) will pay up to £175 million ($230 million) to gain global, exclusive rights to a Phase I monoclonal antibody to treat severe asthma from Johnson & Johnson’s ($JNJ) Janssen. GSK will assume all activities worldwide once Janssen completes an ongoing Phase I trial.

Late last year, the FDA approved GSK’s Nucala (mepolizumab) to treat severe asthma specifically for those with an eosinophilic phenotype. This subset of asthma patients typically have tissue and sputum eosinophilia and the thickening of the basement membrane zone.

In addition to the variable upfront, which presumably hinges on the Phase I outcome, Janssen stands to gain additional, undisclosed development and first commercial sales milestones, in addition to tiered royalties and “further considerations” tied to sales.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

The candidate in question is CNTO 7160, a monoclonal antibody that prevents interleukin-33 from binding to the ST2 receptor (IL-33R); it’s expected to be useful in severe asthma via the regulation of inflammatory cells that are key to asthma such as neutrophils and eosinophils.

“While current options for the treatment of mild to moderate asthma enable patients to achieve good control of their symptoms, there remains significant unmet need in severe patients,” said GSK Respiratory Head Dave Allen in a statement. “The IL-33 receptor antibody joins our diverse respiratory R&D portfolio of targeted biological therapies and offers the potential to block a fundamental driver of the disease.”

Respiratory disease is a core R&D area for GSK along with 5 others including oncology, vaccines, immuno-inflammation, HIV and infectious diseases and rare diseases. The pharma has a pipeline that includes next-gen approaches for asthma, COPD, idiopathic pulmonary fibrosis and acute lung injury.

“Following our recent successful launch of a first-in-class biologic for severe asthma in an eosinophilic population, we plan to investigate this asset’s potential to treat other targeted populations, for which there are currently no effective medicines,” concluded Allen.

- here is the announcement

Related Articles:
GlaxoSmithKline bags an FDA OK for its asthma drug with eyes on a respiratory turnaround
FDA experts endorse Teva's asthma drug, but reject use in key patient group
AstraZeneca’s asthma biologic hits PhIII target, but still behind rivals

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.